AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

Mycobacterium Abscessus Load Reduced by 65% NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial.  The Company previously announced positive preliminary data through Day 51. “We continue to be delighted with the data from this trial.  With just 21
http://bit.ly/2rzOp1x